TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Depreciation & Amortization (CF) came in at $94000.0 in Q1 2026, down 1.05% YoY from $95000.0 in Q1 2025, and down 3.09% on a QoQ basis from $97000.0 in Q4 2025.
TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $94000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 1.05% year-over-year to $94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383000.0 (down 18.68% YoY) and the FY2025 annual result came in at $384000.0, down 24.56% from the prior year.
- Depreciation & Amortization (CF) declined to $94000.0 in Q1 2026, from $97000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $637000.0 in Q4 2023 to a low of $27000.0 in Q1 2023.
- A 5-year average of $182529.4 and a median of $129000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) sank 91.79% — and 2024, when it surged 392.59%.
- Tracing TXMD's Depreciation & Amortization (CF) over 5 years: stood at $309000.0 in 2022, then soared by 106.15% to $637000.0 in 2023, then sank by 84.3% to $100000.0 in 2024, then slipped by 3.0% to $97000.0 in 2025, then retreated by 3.09% to $94000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $94000.0 (Q1 2026), $97000.0 (Q4 2025), and $96000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 95,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95,000.00 |
| Jun 30, 2026 | 95,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Mar 31, 2024 | 133,000.00 |